Embracing Inclusivity: How Biopharmas Connect With LGBTQ+ Employees 6/6/2024

Telix Targets $200M IPO in Hot Radiopharma Market as Biotech Nasdaq Offerings Slow 6/6/2024

You’re More Than Your Job: Finding Self-Worth Outside of Work 6/6/2024

Blocking a protein known as CDK7 could prevent heart damage associated with a commonly used cancer chemotherapy medication, according to a study led by scientists at Washington State University. Importantly, the researchers also found that inhibiting CDK7 could help enhance the medication's cancer-killing capability.

Based on an animal model, the study findings could provide a foundation for future treatment strategies to reduce chemotherapy-related heart toxicity and increase treatment effectiveness.

ASGCT 2024 Comes at Pivotal Time for Gene and Cell Therapy Sector 5/6/2024

Opinion: Can Ketamine Be Safely Used at Home? 5/6/2024

5 DMD Data Readouts to Watch in 2024 5/6/2024

AAVs in Focus at ASGCT: Improved Precision, Targeting Common Diseases 5/6/2024

In an era marked by rapid technological advancement in biomedical engineering, a groundbreaking development is set to revolutionize our approach to drug testing and disease modeling. Researchers from Shanghai University and the University of California Los Angeles have made significant strides in the field of in vitro vascularized organ-on-a-chip systems, offering a promising alternative to traditional methods that rely heavily on animal testing and simplistic two-dimensional cell cultures.

FDA Greenlights BMS, J&J CAR-T Therapies for Earlier Multiple Myeloma Treatment 4/6/2024

A novel immunotherapy approach developed by Ludwig Cancer Research scientists employs a two-pronged attack against solid tumors to boost the immune system’s ability to target and eliminate cancer cells.​​​​​​

The research focuses on an immunotherapy called adoptive cell transfer (ACT), which involves extracting T cells from a patient, enhancing their ability to fight cancer, expanding them in culture and reinfusing them into the patient's body.

Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 3 CROWN trial evaluating LORBRENA® (lorlatinib, a third-generation ALK inhibitor, available in Europe under the brand name LORVIQUA®) versus XALKORI® (crizotinib) in people with previously untreated, anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

ASCO24: Novartis Leukemia Drug Beats Older Drugs in Phase III Readout 5/31/2024

Gilead’s Trodelvy Fails to Reach Primary Endpoint in Confirmatory Trial 5/31/2024

FDA Delays Dupixent Uncontrolled COPD Decision as EU Panel Recommends Approval 5/31/2024

ASCO24 Preview: A Look at Some of the Cancer Meeting’s Hottest Abstracts 5/31/2024

Smaller Biopharma M&A on Upswing, Deals Expected to Continue Through 2024 5/31/2024

Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, announced today that BlueRock's investigational cell therapy bemdaneprocel for the treatment of Parkinson's disease has been granted Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA).

BridgeBio Builds on Positive Phase III Data for Acoramidis in ATTR-CM 5/30/2024

Immunovant Shifts Focus to Other FcRn Inhibitor, Gives Rival Vyvgart Breathing Room 5/30/2024